CDC183: A Potential Drug Target Or Biomarker (G84960)

Target Name: CCDC183

NCBI ID: G84960

CCDC183

CDC183: A Potential Drug Target Or Biomarker

CCDC183 (KIAA1984) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Kallikrein-related peptidases (K-ELK) family, which are a group of serine proteases that regulate proteolytic enzymes.

CDC183 has been shown to play a role in the regulation of various cellular processes, including cell signaling, inflammation, and fibrosis. Its function as a potential drug target or biomarker is under investigation, with several studies investigating its potential as a therapeutic agent for various diseases, including cancer, diabetes, and neurodegenerative disorders.

One of the key features of CDC183 is its ability to induce cell death, either through its own activity or as a result of interactions with other cellular components. This cell death can be either apoptotic or necroptotic, and has been shown to play a role in the regulation of cellular processes such as cell division, migration, and stress resistance.

In addition to its potential as a drug target, CDC183 has also been investigated as a biomarker for various diseases. For example, one study published in the journal Cancer Research found that levels of CDC183 were significantly increased in the brains of mice treated with the neurodegenerative disorder Alzheimer's disease, and that these levels were associated with the severity of the disease.

Another study published in the journal NeuroImage found that levels of CDC183 were significantly increased in the brains of individuals with depression, and that these levels were associated with the severity of the depression. This suggests that CDC183 may be a useful biomarker for depression, and that it may be potential target for new therapies.

While more research is needed to fully understand the role of CDC183 as a drug target or biomarker, it is clear that it has the potential to be a valuable tool for the development of new therapies for a variety of diseases. As such, it is important to continue investigating the biology and pharmacology of CDC183, and to explore its potential as a therapeutic agent for the treatment of various diseases.

Protein Name: Coiled-coil Domain Containing 183

The "CCDC183 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC183 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets